Cargando…
Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma
Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performan...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959276/ https://www.ncbi.nlm.nih.gov/pubmed/36839792 http://dx.doi.org/10.3390/pharmaceutics15020468 |
_version_ | 1784895235354001408 |
---|---|
author | Zilles, Júlia Capp Duarte, Larissa Pedron Ruaro, Thaís Carine Zimmer, Aline Rigon Kulkamp-Guerreiro, Irene Clemes Contri, Renata Vidor |
author_facet | Zilles, Júlia Capp Duarte, Larissa Pedron Ruaro, Thaís Carine Zimmer, Aline Rigon Kulkamp-Guerreiro, Irene Clemes Contri, Renata Vidor |
author_sort | Zilles, Júlia Capp |
collection | PubMed |
description | Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy method (Ultra-Turrax(®)) was used to develop nanoemulsions containing up to 2 mg/mL KDP, 5% rosehip oil, and 7.5% surfactant. Formulations were characterized regarding droplet size, size distribution, pH, density, morphology, KDP content, incorporation efficiency, and stability under different temperature conditions. A scale-up study was conducted. Skin permeation, antioxidant potential, and tyrosinase inhibitory activity were assessed in vitro. Cell viability studies were also performed. Results showed that nanoemulsions containing 1 and 2 mg/mL KDP had incorporation efficiencies greater than 95%, droplet size smaller than 130 nm, suitable size distribution, zeta potential of approximately −10 mV, and good stability over 30 days of refrigerated storage. The nanoemulsion containing 1 mg/mL KDP was chosen for further evaluation because it had lower nanocrystal formation, greater scale-up feasibility and allowed KDP permeation up to the epidermis similarly than observed for 2 mg/mL KDP. This formulation (1 mg/mL KDP) showed antioxidant and depigmenting efficacy, close to that of 1 mM ascorbic acid. No cytotoxicity was observed in formulations concentrations ranging from 0.06% to 1%. |
format | Online Article Text |
id | pubmed-9959276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99592762023-02-26 Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma Zilles, Júlia Capp Duarte, Larissa Pedron Ruaro, Thaís Carine Zimmer, Aline Rigon Kulkamp-Guerreiro, Irene Clemes Contri, Renata Vidor Pharmaceutics Article Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy method (Ultra-Turrax(®)) was used to develop nanoemulsions containing up to 2 mg/mL KDP, 5% rosehip oil, and 7.5% surfactant. Formulations were characterized regarding droplet size, size distribution, pH, density, morphology, KDP content, incorporation efficiency, and stability under different temperature conditions. A scale-up study was conducted. Skin permeation, antioxidant potential, and tyrosinase inhibitory activity were assessed in vitro. Cell viability studies were also performed. Results showed that nanoemulsions containing 1 and 2 mg/mL KDP had incorporation efficiencies greater than 95%, droplet size smaller than 130 nm, suitable size distribution, zeta potential of approximately −10 mV, and good stability over 30 days of refrigerated storage. The nanoemulsion containing 1 mg/mL KDP was chosen for further evaluation because it had lower nanocrystal formation, greater scale-up feasibility and allowed KDP permeation up to the epidermis similarly than observed for 2 mg/mL KDP. This formulation (1 mg/mL KDP) showed antioxidant and depigmenting efficacy, close to that of 1 mM ascorbic acid. No cytotoxicity was observed in formulations concentrations ranging from 0.06% to 1%. MDPI 2023-01-31 /pmc/articles/PMC9959276/ /pubmed/36839792 http://dx.doi.org/10.3390/pharmaceutics15020468 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zilles, Júlia Capp Duarte, Larissa Pedron Ruaro, Thaís Carine Zimmer, Aline Rigon Kulkamp-Guerreiro, Irene Clemes Contri, Renata Vidor Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title | Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title_full | Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title_fullStr | Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title_full_unstemmed | Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title_short | Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma |
title_sort | nanoemulsion containing kojic dipalmitate and rosehip oil: a promising formulation to treat melasma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959276/ https://www.ncbi.nlm.nih.gov/pubmed/36839792 http://dx.doi.org/10.3390/pharmaceutics15020468 |
work_keys_str_mv | AT zillesjuliacapp nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma AT duartelarissapedron nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma AT ruarothaiscarine nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma AT zimmeralinerigon nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma AT kulkampguerreiroireneclemes nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma AT contrirenatavidor nanoemulsioncontainingkojicdipalmitateandrosehipoilapromisingformulationtotreatmelasma |